YAP1 and cancer: Interestingly, as is demonstrated in the studies described above, knockdown of YAP/TAZ or overexpression of LATS2, RASSF1A or hEx is able to sensitize cancer cells to paclitaxel at low concentrations [53,54,80,82,83,87,90,92].